TY - JOUR
T1 - The galen rhinosinusitis cohort
T2 - Chronic rhinosinusitis with nasal polyps affects health-related quality of life
AU - Khan, Asif
AU - Huynh, Thi Minh Thao
AU - Vandeplas, Griet
AU - Joish, Vijay N.
AU - Mannent, Leda P.
AU - Tomassen, Peter
AU - van Zele, Thibaut
AU - Cardell, Lars Olaf
AU - Arebro, Julia
AU - Olze, Heidi
AU - Förster-Ruhrmann, Ulrike
AU - Kowalski, Marek L.
AU - Olszewska-Ziąber, Agnieszka
AU - Fokkens, Wytske
AU - van Drunen, Cornelis
AU - Mullol, Joaquim
AU - Alobid, Isam
AU - Hellings, Peter W.
AU - Hox, Valérie
AU - Toskala, Elina
AU - Scadding, Glenis
AU - Lund, Valerie
AU - Bachert, Claus
N1 - Funding Information:
provided direction for manuscript development, and provided received fees for lectures and grants for research projects from critical feedback and final approval for submission. PT, TvZ, L-OC, Allakos, ALK-Abelló, FAES, Genentech (Roche), GSK, Mylan, JA, HO, UF-R, MLK, AO-Z, WF, CvD, JM, IA, PWH, VH, ET, GS, and Meda Pharma, Menarini, MSD, Novartis, Regeneron Pharma-VL assisted with acquisition and interpretation of the results, ceuticals, Inc., Sanofi Genzyme, UCB, and Uriach Group. IA: reviewed and provided direction for manuscript development, consultant for Roche. ET: advisory board member for Allergan. and provided critical feedback and final approval for submission. GS: received research grants from ALK and GSK; honoraria for articles, consulting, lectures/chairing, and/or advisory boards
Funding Information:
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance provided by Ferdinando Giacco, PhD, and Ronald van Olffen, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Publisher Copyright:
© 2019, International Rhinologic Society. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Chronic rhinosinusitis (CRS) significantly affects health-related quality of life (HRQoL). Few multinational observational studies have evaluated the impact of CRS with nasal polyps (CRSwNP) on patients’ HRQoL. This study aimed to assess HRQoL outcomes (including analyses by disease severity and impact of comorbidities and refractory disease) in CRSwNP patients from a large European database. Methodology: Data were analysed from the Global Allergy and Asthma European Network (GALEN) Rhinosinusitis Cohort, including sociodemographic data, patient-reported disease severity (visual analogue scale), and scores on the 36-Item Short-Form Health Survey (SF-36) questionnaire. Differences in mean SF-36 scores were evaluated between patients with CRSwNP and population norms and between subgroups of interest (disease severity, comorbidity, and refractory disease, defined by a history of sinonasal surgery). Results: Patients with CRSwNP (N = 445) had significantly lower mean SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores vs population norms, demonstrating that CRSwNP negatively affects HRQoL. The presence of comorbidities affected HRQoL, as shown by significant differences in PCS scores in patients with asthma or non-steroidal anti-inflammatory drug-exacerbated respiratory disease, compared with patients without asthma. Patients with moderate-to-severe disease had significantly lower PCS scores than patients with mild disease. Severe disease had a significant impact on MCS score. History of surgery had a clinically meaningful negative effect on HRQoL compared with no history of surgery. Conclusions: CRSwNP patients have significantly lower HRQoL compared with population norms. The impact is greater in patients with greater disease severity, comorbidities, or refractory disease.
AB - Background: Chronic rhinosinusitis (CRS) significantly affects health-related quality of life (HRQoL). Few multinational observational studies have evaluated the impact of CRS with nasal polyps (CRSwNP) on patients’ HRQoL. This study aimed to assess HRQoL outcomes (including analyses by disease severity and impact of comorbidities and refractory disease) in CRSwNP patients from a large European database. Methodology: Data were analysed from the Global Allergy and Asthma European Network (GALEN) Rhinosinusitis Cohort, including sociodemographic data, patient-reported disease severity (visual analogue scale), and scores on the 36-Item Short-Form Health Survey (SF-36) questionnaire. Differences in mean SF-36 scores were evaluated between patients with CRSwNP and population norms and between subgroups of interest (disease severity, comorbidity, and refractory disease, defined by a history of sinonasal surgery). Results: Patients with CRSwNP (N = 445) had significantly lower mean SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores vs population norms, demonstrating that CRSwNP negatively affects HRQoL. The presence of comorbidities affected HRQoL, as shown by significant differences in PCS scores in patients with asthma or non-steroidal anti-inflammatory drug-exacerbated respiratory disease, compared with patients without asthma. Patients with moderate-to-severe disease had significantly lower PCS scores than patients with mild disease. Severe disease had a significant impact on MCS score. History of surgery had a clinically meaningful negative effect on HRQoL compared with no history of surgery. Conclusions: CRSwNP patients have significantly lower HRQoL compared with population norms. The impact is greater in patients with greater disease severity, comorbidities, or refractory disease.
KW - Nasal polyps
KW - Quality of life
KW - Rhinitis
KW - Sinusitis
UR - http://www.scopus.com/inward/record.url?scp=85072849428&partnerID=8YFLogxK
U2 - 10.4193/Rhin19.158
DO - 10.4193/Rhin19.158
M3 - Article
C2 - 31318362
AN - SCOPUS:85072849428
SN - 0300-0729
VL - 57
SP - 343
EP - 351
JO - Rhinology
JF - Rhinology
IS - 5
ER -